Immunovant Change To Inventory vs Change To Account Receivables Analysis

IMVT Stock

USD 24.97 0.94 3.63%

Immunovant financial indicator trend analysis is infinitely more than just investigating Immunovant recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunovant is a good investment. Please check the relationship between Immunovant Change To Inventory and its Change To Account Receivables accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Change To Inventory vs Change To Account Receivables

Change To Inventory vs Change To Account Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunovant Change To Inventory account and Change To Account Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Immunovant's Change To Inventory and Change To Account Receivables is 0.71. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Change To Account Receivables in the same time period over historical financial statements of Immunovant, assuming nothing else is changed. The correlation between historical values of Immunovant's Change To Inventory and Change To Account Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of Immunovant are associated (or correlated) with its Change To Account Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Account Receivables has no effect on the direction of Change To Inventory i.e., Immunovant's Change To Inventory and Change To Account Receivables go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Change To Account Receivables

Most indicators from Immunovant's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.1 M in 2026, despite the fact that Enterprise Value Over EBITDA is likely to grow to (4.68).

	2023	2024	2025	2026 (projected)
Total Operating Expenses	270.2M	438.2M	503.9M	529.1M
Research Development	212.9M	360.9M	415.1M	435.8M

Total Operating Expenses Research Development

Immunovant fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.97	0.98	1.0	0.86	0.89	0.93	0.93	0.99	0.99	1.0	0.02	0.6	-0.9	-0.98	-0.96	0.95	0.89	0.95	0.95	0.24	0.9	-0.03	0.9	-0.86	0.95
Other Current Liab	0.97		0.99	0.97	0.81	0.84	0.92	0.96	0.98	0.99	0.97	-0.06	0.49	-0.86	-0.94	-0.98	0.91	0.87	0.91	0.91	0.14	0.89	-0.02	0.89	-0.84	0.91
Total Current Liabilities	0.98	0.99		0.98	0.82	0.9	0.91	0.96	0.99	1.0	0.98	-0.04	0.51	-0.85	-0.95	-0.97	0.92	0.9	0.91	0.92	0.24	0.88	-0.01	0.88	-0.84	0.92
Total Stockholder Equity	1.0	0.97	0.98		0.86	0.89	0.93	0.92	0.98	0.98	1.0	0.02	0.61	-0.9	-0.98	-0.96	0.95	0.89	0.95	0.95	0.24	0.9	-0.03	0.9	-0.86	0.95
Net Tangible Assets	0.86	0.81	0.82	0.86		0.71	0.94	0.66	0.78	0.83	0.86	0.36	0.82	-0.98	-0.92	-0.76	0.93	0.64	0.95	0.93	0.35	0.98	0.02	0.97	-0.91	0.93
Accounts Payable	0.89	0.84	0.9	0.89	0.71		0.76	0.83	0.89	0.91	0.89	-0.08	0.48	-0.71	-0.84	-0.85	0.81	0.89	0.78	0.81	0.49	0.72	-0.07	0.72	-0.67	0.81
Common Stock Shares Outstanding	0.93	0.92	0.91	0.93	0.94	0.76		0.82	0.89	0.91	0.93	0.13	0.62	-0.94	-0.96	-0.91	0.99	0.74	0.94	0.99	0.2	0.99	0.01	0.99	-0.89	0.99
Other Current Assets	0.93	0.96	0.96	0.92	0.66	0.83	0.82		0.97	0.95	0.93	-0.21	0.35	-0.72	-0.86	-0.97	0.83	0.94	0.81	0.83	-0.01	0.76	-0.05	0.77	-0.71	0.83
Other Stockholder Equity	0.99	0.98	0.99	0.98	0.78	0.89	0.89	0.97		0.99	0.98	-0.11	0.48	-0.83	-0.94	-0.98	0.91	0.92	0.9	0.91	0.15	0.85	-0.06	0.85	-0.79	0.91
Total Liab	0.99	0.99	1.0	0.98	0.83	0.91	0.91	0.95	0.99		0.99	-0.03	0.53	-0.86	-0.95	-0.97	0.92	0.9	0.92	0.92	0.24	0.89	-0.01	0.89	-0.84	0.92
Total Current Assets	1.0	0.97	0.98	1.0	0.86	0.89	0.93	0.93	0.98	0.99		0.02	0.6	-0.9	-0.98	-0.96	0.95	0.89	0.95	0.95	0.24	0.91	-0.03	0.9	-0.86	0.95
Short Long Term Debt Total	0.02	-0.06	-0.04	0.02	0.36	-0.08	0.13	-0.21	-0.11	-0.03	0.02		0.61	-0.28	-0.09	0.17	0.09	-0.1	0.18	0.09	0.17	0.26	0.65	0.18	-0.47	0.08
Property Plant And Equipment Net	0.6	0.49	0.51	0.61	0.82	0.48	0.62	0.35	0.48	0.53	0.6	0.61		-0.81	-0.65	-0.41	0.62	0.47	0.78	0.62	0.3	0.71	-0.01	0.67	-0.72	0.61
Current Deferred Revenue	-0.9	-0.86	-0.85	-0.9	-0.98	-0.71	-0.94	-0.72	-0.83	-0.86	-0.9	-0.28	-0.81		0.95	0.82	-0.93	-0.68	-0.98	-0.93	-0.27	-0.97	0.05	-0.96	0.91	-0.92
Net Debt	-0.98	-0.94	-0.95	-0.98	-0.92	-0.84	-0.96	-0.86	-0.94	-0.95	-0.98	-0.09	-0.65	0.95		0.94	-0.98	-0.81	-0.96	-0.98	-0.28	-0.95	0.03	-0.95	0.89	-0.97
Retained Earnings	-0.96	-0.98	-0.97	-0.96	-0.76	-0.85	-0.91	-0.97	-0.98	-0.97	-0.96	0.17	-0.41	0.82	0.94		-0.92	-0.88	-0.87	-0.92	-0.11	-0.85	0.07	-0.87	0.77	-0.92
Cash	0.95	0.91	0.92	0.95	0.93	0.81	0.99	0.83	0.91	0.92	0.95	0.09	0.62	-0.93	-0.98	-0.92		0.79	0.93	1.0	0.25	0.96	-0.02	0.97	-0.87	1.0
Non Current Assets Total	0.89	0.87	0.9	0.89	0.64	0.89	0.74	0.94	0.92	0.9	0.89	-0.1	0.47	-0.68	-0.81	-0.88	0.79		0.78	0.79	0.06	0.69	-0.04	0.68	-0.66	0.79
Non Currrent Assets Other	0.95	0.91	0.91	0.95	0.95	0.78	0.94	0.81	0.9	0.92	0.95	0.18	0.78	-0.98	-0.96	-0.87	0.93	0.78		0.93	0.26	0.95	-0.1	0.95	-0.89	0.93
Cash And Short Term Investments	0.95	0.91	0.92	0.95	0.93	0.81	0.99	0.83	0.91	0.92	0.95	0.09	0.62	-0.93	-0.98	-0.92	1.0	0.79	0.93		0.25	0.96	-0.02	0.97	-0.87	1.0
Net Receivables	0.24	0.14	0.24	0.24	0.35	0.49	0.2	-0.01	0.15	0.24	0.24	0.17	0.3	-0.27	-0.28	-0.11	0.25	0.06	0.26	0.25		0.24	-0.02	0.25	-0.24	0.23
Common Stock Total Equity	0.9	0.89	0.88	0.9	0.98	0.72	0.99	0.76	0.85	0.89	0.91	0.26	0.71	-0.97	-0.95	-0.85	0.96	0.69	0.95	0.96	0.24		0.07	0.99	-0.94	0.96
Non Current Liabilities Total	-0.03	-0.02	-0.01	-0.03	0.02	-0.07	0.01	-0.05	-0.06	-0.01	-0.03	0.65	-0.01	0.05	0.03	0.07	-0.02	-0.04	-0.1	-0.02	-0.02	0.07		-0.02	-0.36	-0.03
Capital Surpluse	0.9	0.89	0.88	0.9	0.97	0.72	0.99	0.77	0.85	0.89	0.9	0.18	0.67	-0.96	-0.95	-0.87	0.97	0.68	0.95	0.97	0.25	0.99	-0.02		-0.9	0.97
Deferred Long Term Liab	-0.86	-0.84	-0.84	-0.86	-0.91	-0.67	-0.89	-0.71	-0.79	-0.84	-0.86	-0.47	-0.72	0.91	0.89	0.77	-0.87	-0.66	-0.89	-0.87	-0.24	-0.94	-0.36	-0.9		-0.86
Net Invested Capital	0.95	0.91	0.92	0.95	0.93	0.81	0.99	0.83	0.91	0.92	0.95	0.08	0.61	-0.92	-0.97	-0.92	1.0	0.79	0.93	1.0	0.23	0.96	-0.03	0.97	-0.86

Click cells to compare fundamentals

Immunovant Account Relationship Matchups

Immunovant fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	515.6M	405.8M	666.7M	776.2M	892.7M	937.3M
Other Current Liab	24.7M	40.8M	41.3M	51.0M	58.7M	61.6M
Total Current Liabilities	44.5M	43.3M	48.6M	68.8M	79.1M	83.0M
Total Stockholder Equity	469.8M	362.5M	617.8M	707.4M	813.6M	854.2M
Net Tangible Assets	94.1M	391.5M	469.8M	362.5M	416.9M	242.7M
Accounts Payable	18.6M	1.4M	7.2M	17.7M	20.3M	21.3M
Common Stock Shares Outstanding	109.7M	123.1M	138.1M	151.6M	174.3M	93.2M
Liabilities And Stockholders Equity	515.6M	405.8M	666.7M	776.2M	892.7M	937.3M
Other Current Assets	6.3M	26.9M	24.9M	51.2M	58.9M	61.8M
Other Stockholder Equity	824.8M	928.0M	1.4B	1.9B	2.2B	2.3B
Total Liab	45.7M	43.3M	49.0M	68.8M	79.1M	83.0M
Total Current Assets	512.9M	404.3M	665.8M	767.7M	882.8M	927.0M
Accumulated Other Comprehensive Income	404K	852K	1.9M	1.5M	1.7M	1.8M
Short Long Term Debt Total	2.4M	1.2M	138K	98K	88.2K	83.8K
Property Plant And Equipment Net	2.6M	1.5M	595K	942K	1.1M	1.4M
Net Debt	(491.5M)	(375.3M)	(635.2M)	(713.9M)	(642.5M)	(610.4M)
Retained Earnings	(355.4M)	(566.3M)	(825.7M)	(1.2B)	(1.1B)	(1.1B)
Cash	493.8M	376.5M	635.4M	714.0M	821.1M	427.5M
Non Current Assets Total	2.6M	1.5M	942K	8.6M	9.8M	10.3M
Cash And Short Term Investments	493.8M	376.5M	635.4M	714.0M	821.1M	427.5M
Net Receivables	12.9M	885K	5.5M	2.5M	2.9M	4.5M
Common Stock Total Equity	5K	10K	12K	13K	15.0K	8.9K
Non Current Liabilities Total	1.2M	47K	347K	1.1M	988.2K	938.8K
Capital Surpluse	185.3M	590.4M	824.8M	928.0M	1.1B	556.3M
Net Invested Capital	469.8M	362.5M	617.8M	707.4M	813.6M	415.4M
Capital Stock	12K	13K	14K	16K	18.4K	11.0K
Net Working Capital	468.4M	361.0M	617.2M	698.9M	803.7M	413.2M
Short Term Debt	1.1M	1.2M	138K	98K	88.2K	83.8K
Common Stock	12K	13K	14K	16K	18.4K	11.0K
Property Plant Equipment	65K	201K	330K	333K	383.0K	216.3K
Capital Lease Obligations	2.4M	1.2M	138K	98K	88.2K	83.8K
Property Plant And Equipment Gross	2.6M	1.5M	595K	942K	847.8K	1.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC